Sugimura, N, Mizoshita, T. Real-world efficacy of adalimumab and infliximab for refractory intestinal Behçet's disease. Dig Liver Dis. 2019
Suzuki, T, Mizoshita, T. Adalimumab Dose-Escalation Therapy Is Effective in Refractory Crohn's Disease Patients with Loss of Response to Adalimumab, Especially in Cases without Previous Infliximab Treatment. Case Rep Gastroenterol. 2019
Suzuki, T, Mizoshita, T. The efficacy of maintenance therapy after remission induction with tacrolimus in ulcerative colitis with and without previous tumor necrosis factor-α inhibitor. JGH Open. 2019
Mizoshita, T. Prospective comparison of preference and efficacy of adalimumab and infliximab for treating ulcerative colitis naive to antitumor necrosis factor therapy. Medicine (Baltimore). 2017